SUSAN E. KNIGHT - 19 Nov 2025 Form 4 Insider Report for SURMODICS INC (SRDX)

Role
Director
Signature
/s/ John Manders on behalf of Susan E. Knight
Issuer symbol
SRDX
Transactions as of
19 Nov 2025
Net transactions value
$0
Form type
4
Filing time
19 Nov 2025, 18:10:05 UTC
Previous filing
28 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KNIGHT SUSAN E Director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE /s/ John Manders on behalf of Susan E. Knight 19 Nov 2025 0001183157

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRDX Common Stock Disposed to Issuer -37,240 -100% 0 19 Nov 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRDX Employee Stock Option (right to buy) Disposed to Issuer $0 -3,634 -100% $0.000000 0 19 Nov 2025 Common Stock 3,634 $55.24 Direct F3
transaction SRDX Employee Stock Option (right to buy) Disposed to Issuer $0 -4,548 -100% $0.000000 0 19 Nov 2025 Common Stock 4,548 $39.58 Direct F3
transaction SRDX Employee Stock Options (right to buy) Disposed to Issuer $0 -3,196 -100% $0.000000 0 19 Nov 2025 Common Stock 3,196 $53.86 Direct F3
transaction SRDX Employee Stock Option (right to buy) Disposed to Issuer $0 -3,555 -100% $0.000000 0 19 Nov 2025 Common Stock 3,555 $41.81 Direct F3
transaction SRDX Employee Stock Option (right to buy) Disposed to Issuer $0 -5,040 -100% $0.000000 0 19 Nov 2025 Common Stock 5,040 $28.98 Direct F3
transaction SRDX Employee Stock Option (right to buy) Disposed to Issuer $0 -4,155 -100% $0.000000 0 19 Nov 2025 Common Stock 4,155 $31.89 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

SUSAN E. KNIGHT is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Merger Agreement, dated as of May 28, 2024, by and among the Surmodics, Inc. (the "Issuer"), BCE Parent, LLC, ("Parent"), and BCE Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock, par value $0.05 per share ("Common Stock"), that was issued and outstanding immediately prior to the Effective Time was automatically cancelled and converted into the right to receive $43.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). All outstanding restricted stock units ("RSUs") held by the reporting person vested immediately prior to the Effective Time and the reporting person is entitled to receive the Merger Consideration for such vested RSUs.
F2 As a result of the Merger, the reporting person no longer beneficially owns, directly or indirectly, any shares of Common Stock.
F3 Pursuant to the Merger Agreement, at the Effective Time, this unexercised stock option ("Option") was cancelled and automatically converted into the right to receive an amount in cash (without interest) equal to the product of (a) the aggregate number of shares of Common Stock subject to the Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over such Option's applicable per share exercise price, subject to any required tax withholdings.